Brown Brothers Harriman & Co’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13K | Buy |
384
+379
| +7,580% | +$12.6K | ﹤0.01% | 1371 |
|
|
2026
Q1 | $151 | Hold |
5
| – | – | ﹤0.01% | 1780 |
|
|
2025
Q4 | $156 | Hold |
5
| – | – | ﹤0.01% | 1820 |
|
|
2025
Q3 | $101 | Hold |
5
| – | – | ﹤0.01% | 1668 |
|
|
2025
Q2 | $84 | Sell |
5
-395
| -99% | -$6.37K | ﹤0.01% | 1536 |
|
|
2025
Q1 | $6.15K | Buy |
400
+376
| +1,567% | +$6.72K | ﹤0.01% | 1125 |
|
|
2024
Q4 | $529 | Hold |
24
| – | – | ﹤0.01% | 1402 |
|
|
2024
Q3 | $432 | Hold |
24
| – | – | ﹤0.01% | 1380 |
|
|
2024
Q2 | $390 | Buy |
+24
| New | +$370 | ﹤0.01% | 1118 |
|
|
2022
Q4 | – | Sell |
-38
| Closed | – | – | 1492 |
|
|
2022
Q3 | $0 | Buy |
+38
| New | +$336 | ﹤0.01% | 1586 |
|
|
2020
Q3 | – | Sell |
-90
| Closed | -$1K | – | 1033 |
|
|
2020
Q2 | $1K | Buy |
+90
| New | +$1.02K | ﹤0.01% | 950 |
|
|
2019
Q1 | – | Sell |
-441
| Closed | -$7K | – | 1106 |
|
|
2018
Q4 | $7K | Buy |
+441
| New | +$9.04K | ﹤0.01% | 745 |
|
|
2018
Q3 | – | Sell |
-1,499
| Closed | -$36K | – | 884 |
|
|
2018
Q2 | $36K | Hold |
1,499
| – | – | ﹤0.01% | 533 |
|
|
2018
Q1 | $26K | Buy |
+1,499
| New | +$29.3K | ﹤0.01% | 553 |
|
|
2017
Q4 | – | Sell |
-600
| Closed | -$11K | – | 1207 |
|
|
2017
Q3 | $11K | Sell |
600
-525
| -47% | -$11.8K | ﹤0.01% | 656 |
|
|
2017
Q2 | $37K | Hold |
1,125
| – | – | ﹤0.01% | 514 |
|
|
2017
Q1 | $36K | Sell |
1,125
-121
| -10% | -$4.13K | ﹤0.01% | 525 |
|
|
2016
Q4 | $45K | Sell |
1,246
-234
| -16% | -$9.34K | ﹤0.01% | 503 |
|
|
2016
Q3 | $68K | Buy |
1,480
+600
| +68% | +$31.3K | ﹤0.01% | 413 |
|
|
2016
Q2 | $44K | Buy |
880
+41
| +5% | +$2.18K | ﹤0.01% | 469 |
|
|
2016
Q1 | $45K | Sell |
839
-420
| -33% | -$24.6K | ﹤0.01% | 451 |
|
|
2015
Q4 | $83K | Sell |
1,259
-3,148
| -71% | -$195K | ﹤0.01% | 408 |
|
|
2015
Q3 | $249K | Buy |
4,407
+873
| +25% | +$56.6K | ﹤0.01% | 303 |
|
|
2015
Q2 | $209K | Sell |
3,534
-3,830
| -52% | -$236K | ﹤0.01% | 330 |
|
|
2015
Q1 | $459K | Sell |
7,364
-115
| -2% | -$6.69K | ﹤0.01% | 269 |
|
|
2014
Q4 | $430K | Sell |
7,479
-238,770
| -97% | -$13.3M | ﹤0.01% | 278 |
|
|
2014
Q3 | $13.2M | Sell |
246,249
-366
| -0.1% | -$19.4K | 0.05% | 67 |
|
|
2014
Q2 | $12.9M | Sell |
246,615
-716
| -0.3% | -$36.6K | 0.05% | 69 |
|
|
2014
Q1 | $13.1M | Sell |
247,331
-563,969
| -70% | -$26.1M | 0.06% | 66 |
|
|
2013
Q4 | $32.5M | Buy |
811,300
+279,325
| +53% | +$11M | 0.07% | 57 |
|
|
2013
Q3 | $20.1M | Buy |
531,975
+3,800
| +0.7% | +$148K | 0.1% | 55 |
|
|
2013
Q2 | $20.7M | Buy |
+528,175
| New | +$20.6M | 0.1% | 57 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Brown Brothers Harriman & Co's TEVA Position: Q2 2026 in Review
Brown Brothers Harriman & Co increased its Teva Pharmaceuticals (TEVA) stake by 7,580% in Q2 2026, buying an estimated $12.6K and bringing the position to 384 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #1371.
Brown Brothers Harriman & Co first reported a position in TEVA in Q2 2013 and has held it in 32 quarters since. The position peaked at $32.5M in Q4 2013. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Brown Brothers Harriman & Co held 384 shares of Teva Pharmaceuticals worth $13K as of Q2 2026.
- Brown Brothers Harriman & Co bought 379 Teva Pharmaceuticals shares in Q2 2026, an estimated $12.6K.
- Teva Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1371 holding.
- Brown Brothers Harriman & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
- Brown Brothers Harriman & Co's Teva Pharmaceuticals position peaked at $32.5M in Q4 2013.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.